Viralkumar Shah
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 106 | 2025 | 3715 | 15.880 |
Why?
| | Hypoglycemic Agents | 60 | 2025 | 1291 | 11.300 |
Why?
| | Blood Glucose | 74 | 2025 | 2186 | 8.670 |
Why?
| | Blood Glucose Self-Monitoring | 56 | 2025 | 641 | 7.780 |
Why?
| | Insulin | 46 | 2025 | 2409 | 6.130 |
Why?
| | Insulin Infusion Systems | 33 | 2025 | 394 | 6.120 |
Why?
| | Hypoglycemia | 26 | 2025 | 445 | 5.490 |
Why?
| | Diabetes Mellitus, Type 2 | 21 | 2025 | 2531 | 3.990 |
Why?
| | Pancreas, Artificial | 8 | 2025 | 84 | 3.060 |
Why?
| | Biosimilar Pharmaceuticals | 5 | 2024 | 23 | 3.040 |
Why?
| | Insulin Glargine | 7 | 2025 | 84 | 3.010 |
Why?
| | Diabetes Mellitus | 11 | 2025 | 1040 | 2.810 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 60 | 2.600 |
Why?
| | Insulin Aspart | 5 | 2024 | 27 | 2.560 |
Why?
| | Fractures, Bone | 8 | 2024 | 380 | 2.430 |
Why?
| | Bone Density | 11 | 2025 | 489 | 2.390 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 201 | 2.050 |
Why?
| | Adult | 86 | 2025 | 37929 | 2.030 |
Why?
| | Hyperglycemia | 8 | 2024 | 347 | 2.020 |
Why?
| | Humans | 143 | 2025 | 137585 | 1.720 |
Why?
| | Diabetic Retinopathy | 3 | 2024 | 189 | 1.640 |
Why?
| | Consensus | 4 | 2024 | 683 | 1.500 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 7 | 1.500 |
Why?
| | Middle Aged | 58 | 2025 | 33479 | 1.430 |
Why?
| | Young Adult | 43 | 2025 | 13209 | 1.300 |
Why?
| | Diabetes Complications | 4 | 2020 | 227 | 1.270 |
Why?
| | Male | 72 | 2025 | 67762 | 1.250 |
Why?
| | Female | 75 | 2025 | 73304 | 1.230 |
Why?
| | Femur Neck | 4 | 2022 | 61 | 1.220 |
Why?
| | Peptides | 2 | 2025 | 985 | 1.210 |
Why?
| | Obesity | 5 | 2025 | 2992 | 1.200 |
Why?
| | Marijuana Abuse | 2 | 2019 | 233 | 0.920 |
Why?
| | Liraglutide | 1 | 2024 | 30 | 0.910 |
Why?
| | Cannabis | 3 | 2022 | 494 | 0.910 |
Why?
| | Glucose | 6 | 2023 | 1020 | 0.900 |
Why?
| | Adolescent | 35 | 2025 | 21513 | 0.890 |
Why?
| | Glucagon-Like Peptides | 1 | 2025 | 58 | 0.880 |
Why?
| | Treatment Outcome | 16 | 2025 | 10811 | 0.860 |
Why?
| | Risk Factors | 18 | 2024 | 10388 | 0.860 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 63 | 0.820 |
Why?
| | Sweetening Agents | 1 | 2023 | 54 | 0.800 |
Why?
| | Registries | 10 | 2021 | 2035 | 0.790 |
Why?
| | Bone and Bones | 2 | 2023 | 317 | 0.790 |
Why?
| | Bone Remodeling | 2 | 2020 | 75 | 0.790 |
Why?
| | Gastroparesis | 2 | 2019 | 9 | 0.780 |
Why?
| | Vitamin D | 3 | 2014 | 397 | 0.760 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.750 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 2111 | 0.750 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 6 | 0.750 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 14 | 0.740 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.730 |
Why?
| | Patient Satisfaction | 2 | 2025 | 660 | 0.720 |
Why?
| | Automobile Driving | 1 | 2023 | 148 | 0.690 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2024 | 279 | 0.680 |
Why?
| | Osteoporosis | 3 | 2020 | 243 | 0.670 |
Why?
| | Incretins | 1 | 2020 | 22 | 0.670 |
Why?
| | Blindness | 1 | 2020 | 38 | 0.660 |
Why?
| | Aged | 28 | 2025 | 23961 | 0.650 |
Why?
| | Diabetes, Gestational | 1 | 2024 | 318 | 0.650 |
Why?
| | Bone Resorption | 1 | 2020 | 86 | 0.650 |
Why?
| | Feasibility Studies | 1 | 2024 | 956 | 0.650 |
Why?
| | Self-Management | 2 | 2020 | 176 | 0.640 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2025 | 47 | 0.640 |
Why?
| | Hip Fractures | 1 | 2020 | 86 | 0.630 |
Why?
| | Age Factors | 6 | 2020 | 3295 | 0.610 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 42 | 0.600 |
Why?
| | Osteogenesis | 1 | 2020 | 188 | 0.590 |
Why?
| | Absorptiometry, Photon | 5 | 2025 | 259 | 0.590 |
Why?
| | Self Care | 2 | 2018 | 380 | 0.570 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 108 | 0.560 |
Why?
| | Bone Diseases | 1 | 2018 | 62 | 0.560 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 275 | 0.550 |
Why?
| | Quality of Life | 4 | 2024 | 2892 | 0.530 |
Why?
| | Child | 23 | 2025 | 21935 | 0.530 |
Why?
| | Body Mass Index | 6 | 2025 | 2389 | 0.530 |
Why?
| | Drugs, Investigational | 1 | 2017 | 33 | 0.520 |
Why?
| | Calcium | 6 | 2014 | 1199 | 0.510 |
Why?
| | Marijuana Smoking | 1 | 2019 | 252 | 0.500 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 15 | 0.490 |
Why?
| | Accidental Falls | 1 | 2018 | 196 | 0.480 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 9 | 0.470 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 186 | 0.460 |
Why?
| | Weight Loss | 3 | 2025 | 787 | 0.460 |
Why?
| | Retrospective Studies | 13 | 2024 | 15657 | 0.440 |
Why?
| | Gallstones | 1 | 2014 | 33 | 0.430 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5472 | 0.420 |
Why?
| | Glucose Intolerance | 1 | 2015 | 146 | 0.420 |
Why?
| | Insulin Lispro | 2 | 2024 | 39 | 0.410 |
Why?
| | Prospective Studies | 10 | 2025 | 7604 | 0.410 |
Why?
| | Pancreatitis | 1 | 2014 | 134 | 0.400 |
Why?
| | Suicide | 1 | 2020 | 656 | 0.390 |
Why?
| | United States | 11 | 2025 | 14841 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 63 | 0.370 |
Why?
| | Sex Factors | 5 | 2025 | 2071 | 0.370 |
Why?
| | Prediabetic State | 2 | 2025 | 253 | 0.360 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 195 | 0.360 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 259 | 0.360 |
Why?
| | Bromocriptine | 2 | 2025 | 30 | 0.350 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 460 | 0.350 |
Why?
| | Meals | 3 | 2024 | 125 | 0.340 |
Why?
| | Sex Characteristics | 3 | 2025 | 762 | 0.340 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5778 | 0.330 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2025 | 47 | 0.330 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1066 | 0.320 |
Why?
| | Benchmarking | 2 | 2022 | 186 | 0.320 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 135 | 0.310 |
Why?
| | History, 20th Century | 4 | 2025 | 325 | 0.300 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1477 | 0.290 |
Why?
| | Cross-Over Studies | 5 | 2025 | 564 | 0.290 |
Why?
| | Autoantibodies | 2 | 2018 | 1496 | 0.290 |
Why?
| | Diabetic Nephropathies | 2 | 2024 | 294 | 0.290 |
Why?
| | Prevalence | 5 | 2023 | 2734 | 0.270 |
Why?
| | Reference Values | 2 | 2019 | 816 | 0.270 |
Why?
| | India | 4 | 2015 | 195 | 0.270 |
Why?
| | Metformin | 2 | 2025 | 331 | 0.260 |
Why?
| | Phenotype | 1 | 2015 | 3196 | 0.260 |
Why?
| | Risk Assessment | 3 | 2020 | 3457 | 0.260 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.260 |
Why?
| | Case-Control Studies | 5 | 2025 | 3556 | 0.240 |
Why?
| | Solid Waste | 1 | 2025 | 3 | 0.240 |
Why?
| | Pregnancy | 5 | 2025 | 6763 | 0.230 |
Why?
| | Manitoba | 1 | 2024 | 3 | 0.230 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 9 | 0.230 |
Why?
| | Smartphone | 1 | 2025 | 91 | 0.220 |
Why?
| | Phosphates | 3 | 2014 | 182 | 0.220 |
Why?
| | History, 21st Century | 3 | 2025 | 213 | 0.210 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5131 | 0.210 |
Why?
| | Proof of Concept Study | 1 | 2024 | 78 | 0.210 |
Why?
| | Drug Substitution | 1 | 2024 | 54 | 0.210 |
Why?
| | Algorithms | 3 | 2024 | 1704 | 0.210 |
Why?
| | Artificial Organs | 1 | 2023 | 2 | 0.210 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 82 | 0.210 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.210 |
Why?
| | Germany | 2 | 2020 | 121 | 0.200 |
Why?
| | Glycemic Index | 1 | 2022 | 27 | 0.200 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 591 | 0.190 |
Why?
| | Minority Groups | 2 | 2023 | 266 | 0.190 |
Why?
| | Vision Screening | 1 | 2021 | 9 | 0.190 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 36 | 0.180 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3284 | 0.180 |
Why?
| | Gastric Emptying | 1 | 2021 | 38 | 0.180 |
Why?
| | Computer Systems | 2 | 2018 | 45 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7635 | 0.180 |
Why?
| | Exercise | 2 | 2025 | 2057 | 0.180 |
Why?
| | Calibration | 2 | 2018 | 146 | 0.180 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 94 | 0.180 |
Why?
| | Body Composition | 1 | 2025 | 684 | 0.170 |
Why?
| | Biomarkers | 3 | 2023 | 4149 | 0.170 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 2 | 0.170 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 14 | 0.170 |
Why?
| | Regression Analysis | 2 | 2020 | 1024 | 0.170 |
Why?
| | Austria | 1 | 2020 | 6 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2025 | 1993 | 0.170 |
Why?
| | Skiing | 1 | 2021 | 47 | 0.170 |
Why?
| | Vision Disorders | 1 | 2021 | 142 | 0.170 |
Why?
| | Energy Intake | 1 | 2023 | 485 | 0.170 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1946 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 820 | 0.160 |
Why?
| | Psychometrics | 2 | 2021 | 720 | 0.160 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 24 | 0.160 |
Why?
| | RNA Interference | 1 | 2021 | 469 | 0.160 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 157 | 0.160 |
Why?
| | Body Weight | 1 | 2024 | 985 | 0.160 |
Why?
| | Insulin Antibodies | 1 | 2020 | 105 | 0.160 |
Why?
| | Bone Development | 1 | 2019 | 54 | 0.160 |
Why?
| | Postprandial Period | 1 | 2020 | 107 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 303 | 0.150 |
Why?
| | C-Peptide | 1 | 2020 | 163 | 0.150 |
Why?
| | Radius | 1 | 2019 | 39 | 0.150 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 24 | 0.150 |
Why?
| | Healthy Volunteers | 1 | 2019 | 199 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.150 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 25 | 0.150 |
Why?
| | Cancellous Bone | 1 | 2018 | 23 | 0.150 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| | Social Class | 1 | 2020 | 282 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 279 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 129 | 0.140 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 246 | 0.140 |
Why?
| | Postmenopause | 1 | 2020 | 366 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Tibia | 1 | 2019 | 178 | 0.140 |
Why?
| | Health Behavior | 1 | 2023 | 762 | 0.140 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 181 | 0.140 |
Why?
| | Incidence | 1 | 2024 | 2804 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2022 | 364 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2020 | 289 | 0.130 |
Why?
| | Time Factors | 3 | 2023 | 6828 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 43 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 163 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 218 | 0.130 |
Why?
| | Glucagon | 1 | 2017 | 109 | 0.130 |
Why?
| | Hormones | 1 | 2017 | 143 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Biosensing Techniques | 1 | 2018 | 129 | 0.130 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 123 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 268 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1587 | 0.130 |
Why?
| | Telemedicine | 1 | 2025 | 862 | 0.120 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 152 | 0.120 |
Why?
| | Alkaline Phosphatase | 2 | 2014 | 148 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 167 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2021 | 786 | 0.120 |
Why?
| | Health Personnel | 1 | 2022 | 710 | 0.120 |
Why?
| | Drug Overdose | 1 | 2020 | 347 | 0.120 |
Why?
| | Circadian Rhythm | 1 | 2019 | 468 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 377 | 0.120 |
Why?
| | Automation | 2 | 2025 | 95 | 0.120 |
Why?
| | Energy Metabolism | 1 | 2020 | 922 | 0.110 |
Why?
| | Parathyroidectomy | 1 | 2014 | 9 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.110 |
Why?
| | Insulin Detemir | 1 | 2013 | 8 | 0.110 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 58 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 561 | 0.100 |
Why?
| | Insulin, Isophane | 1 | 2013 | 21 | 0.100 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 48 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 105 | 0.100 |
Why?
| | Bionics | 2 | 2023 | 12 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2828 | 0.100 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 13 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 137 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 3958 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1060 | 0.100 |
Why?
| | Suppuration | 1 | 2012 | 9 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 181 | 0.100 |
Why?
| | Abdominal Pain | 1 | 2014 | 145 | 0.100 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 4 | 0.100 |
Why?
| | Diabetic Foot | 1 | 2012 | 24 | 0.100 |
Why?
| | Cohort Studies | 2 | 2020 | 5742 | 0.090 |
Why?
| | Dogs | 1 | 2013 | 413 | 0.090 |
Why?
| | Hemoglobins | 1 | 2014 | 353 | 0.090 |
Why?
| | Leptin | 1 | 2013 | 236 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2012 | 37 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 90 | 0.090 |
Why?
| | Cholelithiasis | 1 | 2011 | 38 | 0.090 |
Why?
| | Swine | 1 | 2013 | 775 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 692 | 0.080 |
Why?
| | Osteomyelitis | 1 | 2012 | 132 | 0.080 |
Why?
| | Adenoma | 1 | 2012 | 230 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2236 | 0.080 |
Why?
| | Animals | 4 | 2018 | 36940 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1996 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4565 | 0.070 |
Why?
| | Pilot Projects | 3 | 2021 | 1710 | 0.070 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 400 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1329 | 0.070 |
Why?
| | Recycling | 1 | 2025 | 5 | 0.060 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 57 | 0.060 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 99 | 0.050 |
Why?
| | Life Style | 1 | 2025 | 490 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1289 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 43 | 0.050 |
Why?
| | Needles | 1 | 2022 | 59 | 0.050 |
Why?
| | Child, Preschool | 3 | 2024 | 11074 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1809 | 0.050 |
Why?
| | Off-Label Use | 1 | 2021 | 52 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 186 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1060 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 329 | 0.040 |
Why?
| | Sodium | 1 | 2021 | 217 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 87 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 500 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 171 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 310 | 0.040 |
Why?
| | Individuality | 1 | 2019 | 156 | 0.030 |
Why?
| | Skin | 1 | 2022 | 752 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 691 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1468 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 560 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 402 | 0.030 |
Why?
| | Prognosis | 1 | 2025 | 4030 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 318 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2020 | 267 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 601 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 581 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2024 | 1208 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 499 | 0.030 |
Why?
| | Culture | 1 | 2015 | 128 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2057 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 30 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 746 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 60 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 257 | 0.030 |
Why?
| | Calcifediol | 1 | 2012 | 33 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2167 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1347 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2691 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 186 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 361 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 24 | 0.020 |
Why?
| | Research Design | 1 | 2017 | 1139 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 150 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2757 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1069 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 281 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9465 | 0.010 |
Why?
| | Mice | 1 | 2018 | 17787 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|